Quantcast

Latest Aethlon Medical Inc. Stories

2014-09-22 12:28:31

SAN DIEGO, Sept. 22, 2014 /PRNewswire/ -- Aethlon Medical, Inc. (OTCQB: AEMD), the pioneer in developing targeted therapeutic devices to address infectious disease, cancer and other life-threatening conditions, disclosed today that the Defense Advanced Research Projects Agency (DARPA) has informed the Company that it plans to exercise an option to proceed with year four of a five-year $5.9 million contract that was awarded to Aethlon on September 30, 2011 under DARPA's Dialysis-Like...

2014-09-17 16:27:04

SAN DIEGO and PRINCETON, N.J., Sept. 17, 2014 /PRNewswire/ -- Aethlon Medical, Inc. (NASDAQ:OTCQB:AEMD), the pioneer in developing targeted therapeutic devices to address infectious disease, cancer and other life-threatening conditions, and its diagnostic subsidiary, Exosome Sciences, Inc. (ESI), disclosed today that each company will be presenting at the 2014 Exosomes & SingleCell Analysis Summit. http://photos.prnewswire.com/prnvar/20130912/LA78266LOGO On September 18(th),...

2014-09-10 08:32:21

SAN DIEGO and NEW YORK, Sept. 10, 2014 /PRNewswire/ -- Aethlon Medical, Inc., (NASDAQ:OTCQB: AEMD), the pioneer in developing targeted therapeutic devices to address infectious disease, cancer and other life-threatening conditions, announced today a suite of online corporate communication channels to maintain on-going direct communication with shareholders and other interested parties. The Company has launched official portals on social media channels including Facebook, Twitter,...

2014-09-08 08:31:27

SAN DIEGO and PRINCETON, N.J., Sept. 8, 2014 /PRNewswire/ -- Aethlon Medical, Inc. (NASDAQ:OTCQB:AEMD), and its diagnostic subsidiary, Exosome Sciences, Inc. (ESI), announced today that ESI researchers have developed and initially validated a lectin-based diagnostic platform that is able to isolate exosome-based biomarkers underlying a broad-spectrum of oncology indications. Aethlon Medical develops targeted therapeutic devices to address infectious disease, cancer and other...

2014-09-02 12:28:32

SAN DIEGO, Sept. 2, 2014 /PRNewswire/ -- Aethlon Medical, Inc. (NASDAQ:OTCQB: AEMD), the pioneer in developing targeted therapeutic devices to address infectious disease, cancer and other life-threatening conditions, announced today that it has received independent internal review board (IRB) approval to initiate human clinical studies of Hemopurifier® therapy at DaVita MedCenter Dialysis located in Houston, Texas. http://photos.prnewswire.com/prnvar/20090325/LA88762LOGO-b...

2014-08-06 12:28:09

SAN DIEGO, Aug. 6, 2014 /PRNewswire/ -- Aethlon Medical, Inc. (OTCQB: AEMD), today released the following note authored by its Chairman and CEO, Jim Joyce. http://photos.prnewswire.com/prnvar/20090325/LA88762LOGO-b The current ebola outbreak in West Africa demonstrates the urgent need for therapeutic strategies to defend against emerging pandemic threats. It also highlights why the Department of Health and Human Services (HHS) has shifted the focus of government biodefense and...

2014-06-25 12:29:13

SAN DIEGO, June 25, 2014 /PRNewswire/ -- Aethlon Medical, Inc. (OTCQB: AEMD), the pioneer in creating medical devices that target unmet therapeutic needs in infectious disease and cancer, announced today that the presentation made by Company Chairman and CEO, Jim Joyce at The Wall Street Analyst Forum on June 19(th), is now available at www.aethlonmedical.com. A link to Mr. Joyce's presentation, including both the audio and slide presentation, is accessible at...

2014-06-17 12:30:02

SAN DIEGO, June 17, 2014 /PRNewswire/ -- Aethlon Medical, Inc. (OTCQX:AEMD), the pioneer in developing selective therapeutic filtration devices to address infectious disease, cancer and other life-threatening conditions, announced today that the Company's Chairman and Chief Executive Officer, Jim Joyce, will present at The Wall Street Analyst Forum 25(th) Annual Institutional Investor Conference on Thursday, June 19(th), at 12:05 PM EDT. Mr. Joyce's presentation will include an...

2014-06-10 08:30:28

POINT ROBERTS, Wash. and NEW YORK, June 10, 2014 /PRNewswire/ -- Investorideas.com, a global news source covering leading sectors including biotech and medical technology issues a Q&A interview with Mr. James A. Joyce ,Chairman and CEO of Aethlon Medical, Inc. (OTCBB: AEMD). Mr. Joyce shares insight into the emerging Immuno-Oncology market and the opportunity it represents. Q: Investorideas.com How did Aethlon Medical become involved in cancer research? A: James A. Joyce,...

2014-05-20 08:33:24

SAN DIEGO, May 20, 2014 /PRNewswire/ -- Aethlon Medical, Inc. (OTCQX:AEMD), the pioneer in developing selective therapeutic filtration devices to address infectious disease, cancer and other life-threatening conditions, announced today that it has entered into a definitive agreement with DaVita Clinical Research( )(DCR) to provide clinical management services to support the forthcoming feasibility study of the Aethlon Hemopurifier®. The Hemopurifier is a first-in-class therapeutic...


Word of the Day
virgule
  • A punctuation mark (/) used to separate related items of information.
  • A little rod; a twig.
This word comes from the Late Latin 'virgula,' accentual mark, a diminutive of 'virga,' rod.
Related